Pressure BioSciences (OTCMKTS:PBIO) versus Adagio Medical (NASDAQ:ADGM) Financial Contrast

Adagio Medical (NASDAQ:ADGM) and Pressure BioSciences (OTCMKTS:PBIO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk and profitability.

Profitability

This table compares Adagio Medical and Pressure BioSciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Adagio Medical	N/A	-791.01%	-199.58%
Pressure BioSciences	N/A	N/A	N/A

Insider & Institutional Ownership

48.1% of Adagio Medical shares are held by institutional investors. Comparatively, 0.0% of Pressure BioSciences shares are held by institutional investors. 5.2% of Adagio Medical shares are held by insiders. Comparatively, 10.8% of Pressure BioSciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Adagio Medical and Pressure BioSciences, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adagio Medical	1	0	0	0	1.00
Pressure BioSciences	0	0	0	0	0.00

Volatility & Risk

Adagio Medical has a beta of 0.14, suggesting that its stock price is 86% less volatile than the S&P 500. Comparatively, Pressure BioSciences has a beta of -0.2, suggesting that its stock price is 120% less volatile than the S&P 500.

Earnings & Valuation

This table compares Adagio Medical and Pressure BioSciences”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adagio Medical	$600,000.00	20.11	-$75.04 million	($0.51)	-1.54
Pressure BioSciences	$1.98 million	0.01	-$29.31 million	($0.96)	0.00

Pressure BioSciences has higher revenue and earnings than Adagio Medical. Adagio Medical is trading at a lower price-to-earnings ratio than Pressure BioSciences, indicating that it is currently the more affordable of the two stocks.

Summary

Pressure BioSciences beats Adagio Medical on 6 of the 11 factors compared between the two stocks.

About Adagio Medical

Adagio Medical Holdings, Inc., a developmental stage medical device company, focuses on the development and commercialization of ablation technologies for the treatment of cardiac arrhythmias. It offers treatment for cardiac arrhythmias, including atrial fibrillation, atrial flutter, and ventricular tachycardia. The company’s product portfolio includes iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and accessories; vCLAS ventricular ULTC catheter; and Cryopulse atrial pulsed-field cryoablation catheter and accessories. The company is based in Laguna Hills, California.

About Pressure BioSciences

Pressure BioSciences, Inc. develops and sells pressure-based platform solutions in the North America, Europe, and Asia. The company's pressure cycling technology (PCT) technology uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control the actions of molecules in biological samples, including cells and tissues from human, animal, plant, and microbial sources. It offers Barocycler instrumentations comprising Barocycler 2320EXT, Barocycler HUB880, Barocycler HUB440, and the Shredder SG3. The company also distributes cell disruption equipment, parts, and consumables. In addition, it offers Barocycler consumable products, such as PCT MicroTubes, PCT MicroCaps, PCT-Micro Pestle, and pressure used to lyse samples for extraction tubes, as well as application specific kits, including consumable products and reagents. The company serves researchers at academic laboratories, government agencies, biotechnology companies, pharmaceutical firms, and other life science institutions. It has collaborations with RedShiftBio Inc.; Inova Schar Cancer Center; NYU; Leica Microsystems, GmbH; Steinbeis Centre for biopolymer analysis and biological mass spectrometry; The Ohio State University; University of Delaware; and Cedars Sinai Medical Center. The company was formerly known as Boston Biomedica, Inc. and changed its name to Pressure BioSciences, Inc. in September 2014. The company was incorporated in 1978 and is based in South Easton, Massachusetts.